Table 4.
Pharmacological therapy for hypertension.
| Hypertension patients 26 (%) |
Imatinib + dasatinib group 13 (%) |
Nilotinib group 13 (%) |
p | |
|---|---|---|---|---|
| ACE inhibitors/ARBs | 19 (73.07%) | 8 (61.54) | 11 (84.62) | 0.378 |
| Beta-blockers | 7 (26.92%) | 5 (38.46) | 2 (15.38) | 0.378 |
| Calcium antagonists | 7 (26.92%) | 3 (23.08) | 4 (30.77) | 1 |
| Diuretics | 6 (23.07%) | 3 (23.08) | 3 (23.08) | 1 |
Antihypertensive drugs used in patients with HT. They are distinguished by TKI groups (imatinib + dasatinib vs. nilotinib).
ACE angiotensin-converting enzyme, ARB angiotensin receptor blocker.